Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

NCT04602065 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Due to the company's development strategy adjustment, Innovent Biologics has decided not to continue this study after consultation with investigators.

Conditions

Extranodal NK/T Cell Lymphoma, Nasal Type

Interventions

DRUG: IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.